Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P020025/S146

Blazer II XP Cardiac Ablation Catheter and Cable

Boston Scientific · Decision date Aug 14, 2025

FDA DECISIONP020025/S146

What did the FDA approve?

FDA records P020025/S146 as a supplement to PMA P020025, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 14, 2025.

FDA approval order statement

for a manufacturing site located at Boston Scientific de Costa Rica, S.R.L., El Coyol Alajuela, Coyol, Costa Rica (FEI: 3007695959) to perform ethylene oxide sterilization activities
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Aug 14, 2025
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P020025/S146
Regulatory pathway
PMA supplement
Product code
OAD
Decision code
APPR
Decision date
Aug 14, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P020025/S146 received

    Application receipt date recorded by FDA.

  2. P020025/S146 · FDA decision

    Normal 180 Day Track No User Fee

  3. P020025/S147 · Related supplement

    RHYTHMIA HDx Ablation Connection Box (for INTELLAGEN) (M004RA65010); Rhythmia HDx Ablation Connection Box (Maestro)

Timeline entries are records held by MedtechLedger for P020025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P020025

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA supplementOct 17, 2025FDA

Explore the linked device profile

Other records with product code OAD

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Irvine Biomedical,Inc.(Ibi)PMA supplementSep 3, 2026FDA
Biosense Webster, Inc.PMA supplementSep 2, 2026FDA
Ampere GeneratorP040042/S059
Irvine Biomedical,Inc.(Ibi)PMA supplementAug 7, 2026FDA
Ampere GeneratorP060019/S059
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records